Melinta Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 09, 2019 16:00 ET
|
Melinta Therapeutics
~ Revenue of $14.1 million, Including Net Product Sales of $11.8 million, for the First Quarter 2019 ~ ~ Reduction of Operating Expenses of 34 Percent, or $19.8 million, Year-Over-Year ~ ~...
Melinta Therapeutics to Present at Making a Difference in Infectious Diseases (MAD-ID) 2019 Annual Meeting
May 07, 2019 07:30 ET
|
Melinta Therapeutics
MORRISTOWN, N.J., May 07, 2019 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to...
Arch Biopartners Announces Issuance of U.S. Patent for Its Novel Antibacterial Drug AB569, Designed to Target Chronic Infection and Antibiotic Resistance
March 27, 2018 09:08 ET
|
Arch Biopartners
TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCBB:ACHFF), announced today that the U.S. Patent and Trademark Office has issued U.S....
Arch Biopartners Arranges Convertible Note Financing
February 08, 2018 07:30 ET
|
Arch Biopartners
TORONTO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:ARCH) (OTCBB:ACHFF), announced it has arranged a non-brokered, unsecured convertible note...
Melinta Therapeutics’ Topical Radezolid Well Tolerated in Phase 1 Study for Treatment of Acne
October 10, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
New Elsevier Book Addresses Challenges of Microbial Drug Resistance
March 13, 2017 14:00 ET
|
Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - March 13, 2017) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of...
ContraFect Announces Presentation of Data at ASM Microbe 2016
June 08, 2016 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - June 08, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...
ContraFect to Present at Jefferies 2016 Healthcare Conference
June 01, 2016 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - June 01, 2016) -
ContraFect Corporation
(NASDAQ: CFRX)
(NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of...
Melinta Therapeutics Raises $70 Million to Support Delafloxacin NDA and Selection of Multi-Drug Resistant Gram-Negative Candidates from RX-04 Platform
February 10, 2014 07:30 ET
|
Melinta Therapeutics
NEW HAVEN, Conn, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the closing of a $70 Million Series 3 equity
financing. Current investor, Vatera Healthcare Partners,...